Clinical trials: Emphysema
Lung Cancer, Pneumothorax
Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes
Discharging patients home with air leak and chest tube to portable drainage device after thoracic resection is cost effective and safe without compromising patients outcome or satisfaction.
- Conditions
- Lung Cancer, Pneumothorax, Subcutaneous Emphysema
- Trial name
- NCT01551082
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alliance of Cardiothoracic and Vascular Surgeons
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
The purpose of this research study is to learn about the safety of transplanting lungs obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a breathing machine or ventilator to deliver oxygen) and…
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- NCT01615484
- Testing
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of North Carolina, Chapel Hill
Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis
Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients
The primary objective is to comparatively evaluate the isolated effects of a long-acting beta2-adrenergic (formoterol fumarate 12µg b.i.d.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Chronic Bronchitis, Pulmonary Emphysema
- Trial name
- NCT00680056
- Testing
- Formoterol plus Tiotropium
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Federal University of São Paulo
Alpha 1-Antitrypsin Deficiency
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.
- Trial name
- STAMP (NCT00301366)
- Testing
- alpha-1 proteinase inhibitor (human)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Grifols Therapeutics LLC
Emphysema
Prostaglandin Inhibition for Emphysema
The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in…
- Trial name
- PIE (NCT02006576)
- Testing
- 600 mg ibuprofen three times daily for 48 weeks
- Where
- 5 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Emphysema
Hypoxic Pulmonary Vasoconstriction Pilot Study
The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction…
- Trial name
- NCT03733470
- Testing
- Sildenafil study group
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eric A. Hoffman
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
COPD, Emphysema
Anti-Platelets in Chronic Obstructive Pulmonary Disease
This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e.
- Conditions
- COPD, Emphysema, Emphysema or COPD
- Trial name
- NCT05567562
- Testing
- dual anti-platelet therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic…
- Trial name
- NCT02948582
- Testing
- Glycopyrrolate Inhalation Solution12.5μg, Glycopyrrolate Inhalation Solution 50μg, Glycopyrrolate Inhalation Solution 100μg
- Volunteers
- 42 people
- Sponsor
- Sunovion Respiratory Development Inc.
COPD, Emphysema
Bronchitis and Emphysema Advice and Training to Reduce Hospitalization
EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to…
- Trial name
- BREATH (NCT00395083)
- Testing
- COPD Self-management Education
- Where
- 22 sites in United States
- Volunteers
- 426 people
- Sponsor
- US Department of Veterans Affairs
Alpha1-Antitrypsin Deficiency
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC…
- Trial name
- NCT04722887
- Testing
- Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Grifols Therapeutics LLC